Show simple item record

dc.contributor.authorO'Connor, JPBen_US
dc.contributor.authorRobinson, SPen_US
dc.contributor.authorWaterton, JCen_US
dc.date.accessioned2020-06-09T12:01:54Z
dc.date.issued2019-03
dc.identifier.citationThe British journal of radiology, 2019, 92 (1095), pp. 20180642 - ?
dc.identifier.issn0007-1285
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3710
dc.identifier.eissn1748-880X
dc.identifier.doi10.1259/bjr.20180642
dc.description.abstractHypoxia is known to be a poor prognostic indicator for nearly all solid tumours and also is predictive of treatment failure for radiotherapy, chemotherapy, surgery and targeted therapies. Imaging has potential to identify, spatially map and quantify tumour hypoxia prior to therapy, as well as track changes in hypoxia on treatment. At present no hypoxia imaging methods are available for routine clinical use. Research has largely focused on positron emission tomography (PET)-based techniques, but there is gathering evidence that MRI techniques may provide a practical and more readily translational alternative. In this review we focus on the potential for imaging hypoxia by measuring changes in longitudinal relaxation [R<sub>1</sub>; termed oxygen-enhanced MRI or tumour oxygenation level dependent (TOLD) MRI] and effective transverse relaxation [R<sub>2</sub>*; termed blood oxygenation level dependent (BOLD) MRI], induced by inhalation of either 100% oxygen or the radiosensitising hyperoxic gas carbogen. We explain the scientific principles behind oxygen-enhanced MRI and BOLD and discuss significant studies and their limitations. All imaging biomarkers require rigorous validation in order to translate into clinical use and the steps required to further develop oxygen-enhanced MRI and BOLD MRI into decision-making tools are discussed.
dc.formatPrint-Electronic
dc.format.extent20180642 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectOxygen
dc.subjectContrast Media
dc.subjectMagnetic Resonance Imaging
dc.subjectBiomarkers
dc.subjectTumor Hypoxia
dc.titleImaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.
dc.typeJournal Article
dcterms.dateAccepted2018-09-25
rioxxterms.versionofrecord10.1259/bjr.20180642
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe British journal of radiology
pubs.issue1095
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.publication-statusPublished
pubs.volume92en_US
pubs.embargo.termsNot known
icr.researchteamPre-Clinical MRIen_US
icr.researchteamQuantitative Biomedical Imagingen_US
dc.contributor.icrauthorRobinson, Simonen
dc.contributor.icrauthorO'Connor, James Patricken


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record